For years, Taiwan Liposome Co. Ltd. (TLC) has been waiting patiently to enter the much bigger mainland China market, and recently sealed a deal with Jixi Biotechnology Partners to commercialize in China several assets that are mostly under development in the US.
"We have been in discussions with many pharma companies, big and small as well as mid-sized ones, and striking a deal has been a tough process," admitted TLC